Assenagon Asset Management S.A. Decreases Stock Holdings in CytomX Therapeutics, Inc. $CTMX

Posted by Geri Gentry on Jul 2nd, 2026

Assenagon Asset Management S.A. reduced its position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Free Report) by 38.6% in the first quarter, HoldingsChannel reports. The institutional investor owned 364,173 shares of the biotechnology company’s stock after selling 228,523 shares during the quarter. Assenagon Asset Management S.A.’s holdings in CytomX Therapeutics were worth $1,712,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in CTMX. Hsbc Holdings PLC purchased a new stake in CytomX Therapeutics in the fourth quarter worth $52,000. Seven Fleet Capital Management LP purchased a new position in shares of CytomX Therapeutics during the fourth quarter valued at about $208,000. Empowered Funds LLC bought a new position in CytomX Therapeutics in the fourth quarter worth about $133,000. XTX Topco Ltd raised its stake in CytomX Therapeutics by 63.9% in the fourth quarter. XTX Topco Ltd now owns 47,991 shares of the biotechnology company’s stock worth $204,000 after buying an additional 18,705 shares in the last quarter. Finally, Virtus Investment Advisers LLC purchased a new stake in CytomX Therapeutics in the fourth quarter worth about $270,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. JPMorgan Chase & Co. raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $7.00 to $12.00 in a research report on Monday, March 16th. Wolfe Research began coverage on CytomX Therapeutics in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 target price for the company. Barclays raised their target price on CytomX Therapeutics from $10.00 to $16.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Piper Sandler lifted their price target on CytomX Therapeutics from $10.00 to $12.00 and gave the company an “overweight” rating in a research report on Monday, March 23rd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $12.10.

Get Our Latest Analysis on CytomX Therapeutics

CytomX Therapeutics Price Performance

Shares of NASDAQ CTMX opened at $3.60 on Thursday. CytomX Therapeutics, Inc. has a 1 year low of $1.72 and a 1 year high of $8.21. The stock has a market cap of $612.68 million, a P/E ratio of -8.78 and a beta of 2.08. The firm has a 50-day moving average of $3.60 and a 200 day moving average of $4.41.

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business had revenue of $10.26 million for the quarter, compared to analyst estimates of $4.68 million. CytomX Therapeutics had a negative net margin of 166.40% and a negative return on equity of 36.61%. Research analysts expect that CytomX Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

CytomX Therapeutics Profile

(Free Report)

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.